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Introduction: Transcatheter arterial chemoembolization (TACE) plus thermal ablation has been widely used recently
in the treatment of hepatocellular carcinoma (HCC). In this study, we aimed to compare results of the combination
of TACE and percutaneous thermal ablation with those of hepatectomy in patients with HCC.
Methods: The clinical data of 137 HCC patients who sequentially received TACE and computed tomography
(CT)-guided percutaneous thermal ablation as an initial curative treatment (combination group) and 148 matched
HCC patients who received hepatectomy (surgery group) between 2004 and 2011 were collected and analyzed.
After TACE, multiphase contrast-enhanced CT was performed to identify the total number of tumors as well as lipiodol
deposition in the liver. Survival was calculated by using the Kaplan-Meier method and compared by using the log-rank
test. The prognostic factors were assessed with multivariate Cox proportional hazards regression analysis.
Results: Of all 285 patients, 225 (79.0 %) had cancerous lesions ≤ 5 cm in diameter. In preoperative contrast-enhanced
CT or magnetic resonance imaging, the number of tumors was 1–4 for each patient. The 1-, 3-, and 5-year overall
survival rates were 95, 74 %, and 67 % in the combination group and 88, 66, and 47 % in the surgery group, respectively
(P = 0.004); the corresponding recurrence-free survival rates for the two groups were 92, 69, and 61 % and 75, 58, and
44 %, respectively (P = 0.001). In the multivariate analysis, treatment allocation was an independent prognostic factor for
survival. Only 60 patients in the combination group had sufficient imaging data, and 135 new lesions with lipiodol
deposition were diagnosed as malignancies in 22 of 60 patients, whereas 20 new lesions were found in 11 of 148
patients in the surgery group.
Conclusion: The combination of TACE and CT-guided percutaneous thermal ablation for HCC improves survival of
HCC patients compared with hepatectomy.
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Hepatocellular carcinoma (HCC) is one of the most
common cancers and is a primary contributor to cancer-
related death in the world; new treatment modalities are
needed to improve the survival of HCC patients [1–3].
Although hepatectomy is an effective treatment for
HCC, it is also invasive and not always repeatable. For
HCC smaller than 2 cm in diameter, radiofrequency abla-
tion (RFA) achieved the same efficacy as surgery [4]. As a
preoperative examination, lipiodol computed tomography
(CT) also contributes to the detection of additional liver
lesions after transcatheter arterial chemoembolization
(TACE) [5–7].
The combination of TACE and RFA improves the sur-
vival of HCC patients compared with RFA alone [8].
However, few studies have compared the results of
TACE plus thermal ablation with those of hepatectomy
in patients with comparable characteristics [9]. In this
retrospective study, we aimed to investigate the long-
term outcomes of TACE combined with CT-guided per-
cutaneous thermal ablation and hepatectomy as the
initial curative treatment for resectable HCC.
Patients and Methods
Patient selection and patient characteristics
This comparative study collected and retrospectively ana-
lyzed the patient characteristics from our electronic med-
ical database. The study was approved by the Institutional
Review Board of Sun Yat-sen University Cancer Center.
Contrast-enhanced CT and magnetic resonance im-
aging (MRI) are the most common imaging techniques
for the diagnosis of HCC. The number of tumors and
tumor size were comparable between the two groups,
as observed via preoperative imaging. The tumor num-
ber and tumor size were assessed by using contrast-
enhanced CT or MRI prior to TACE or hepatectomy;
however, additional HCCs that were detected via lipio-
dol CT or pathologic examination were not included.
Dynamic contrast-enhanced CT was performed with a
16-detector row scanner (Brilliance 16, Philips Medical
Systems, Best, the Netherlands) or a 64-detector row
CT scanner (Brilliance 64, Philips Medical Systems,
Best, the Netherlands). MRI examination was per-
formed with a 1.5-T MR system (Magnetom Symphony,
Siemens, Erlangen, Germany) with an 18-channel body
surface phased-array coil. MRI scan was also performed
with a 3 T whole-body scanner (Tim Trio, Siemens,
Erlangen, Germany) in some patients by using the body
coil to transmit radiofrequency pulses and a 12-channel
phased-array head coil to receive signals. The liver was
imaged in at least the axial plane in all patients, and
the gadoxetic acid (Primovist, Bayer Schering Pharma,
Germany) was administrated at a dose of 0.1 mL/kg
through the antecubital vein.The diagnosis of HCC was based on the criteria used
by the European Association for the Study of the Liver
[10]: (1) two imaging techniques showing typical features
of HCC, (2) positive findings on one imaging study together
with an alpha fetoprotein (AFP) level of > 400 ng/mL, or (3)
a histological diagnosis of HCC.
The inclusion criteria were as follows: (1) patients at
18–75 years old; (2) patients with HCC of 1–10 cm in
diameter and 1–4 lesions in preoperative imaging (prior
to TACE or surgery); (3) patients with Eastern Coopera-
tive Oncology Group performance score of 0 or 1; (4)
patients with liver function Child-Pugh A or B; and (5)
patients without portal vein tumor thrombus, lymph
node metastases, or distant metastases.
The exclusion criteria were as follows: (1) patients with
other malignancies; (2) patients with liver function Child-
Pugh C; (3) patients with less than 3 months of life expect-
ancy or follow-up; (4) patients with uncontrolled severe
diabetes, acute infection, or allergy to iodine; or (5) patients
with a bleeding tendency (prothrombin time-international
normalized ratio [PT-INR] > 2.5 or platelet < 50 × 109) or
severe jaundice (total bilirubin > 170 μmol/L).
A total of 137 patients who received TACE and percu-
taneous thermal ablation (combination group) as well as
148 patients who received hepatectomy (surgery group)
between January 2004 and December 2011 were involved
(Fig. 1). The patients in the surgery group were selected
from more than 10,000 HCC patients undergoing hepatec-
tomy to match the patients in the combination group and
reduce confounding factors. The patients in the two
groups were matched according to age, sex, tumor size,
tumor number, liver function, and other factors prior to
TACE or surgery (Table 1).
Treatments
TACE and lipiodol CT
TACE was performed prior to ablation and by following
previously described techniques [11]. The volume of lipio-
dol and the dose of chemotherapeutics depended on the
volume and blood supply of the targeted tumor, as well as
the Eastern Cooperative Oncology Group (ECOG) per-
formance status and liver function of the patients. The
emulsion of 5–15 mL of lipiodol, 40–60 mg of epirubicin,
4 mg of mitomycin C, 200–400 mg of carboplatin, and
3 mL of saline solution was infused through the target
hepatic arteries, without retrograde flow. Two weeks to
1 month after TACE, baseline CT and multiphase (arterial,
portal, and delayed phases) contrast-enhanced CT (lipio-
dol CT) were performed to identify the total number of
tumors as well as lipiodol deposition in the liver. We then
treated all confirmed cancerous lesions. The tiny HCC
was defined as tumors ≤ 5 mm in diameter.
For lipiodol deposition in the liver, we first excluded
calcification, intrahepatic calculi, hemangioma, patchy
Fig. 1 Chart showing the treatment strategy of hepatocellular carcinoma (HCC). PVTT, portal vein tumor thrombus; TACE, transcatheter arterial
chemoembolization; CT, computed tomography
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satellite lesions within the primary lesion. Tiny HCC
with lipiodol deposition was confirmed by at least two
radiologists in our department who each had more than
4 years of experience in radiology. According to peri-
operative CT or MRI, the radiologists focused on detect-
ing tiny HCC. Follow-up CT and/or MRI scans, AFP
test, and PET-CT were used to differentiate lesions with
lipiodol deposition or high CT value if necessary. Any
disagreement in the diagnosis was settled by consulting
with other experienced radiologists in our department.
Percutaneous thermal ablation
CT-guided percutaneous thermal ablation included RFA
and microwave ablation in our study. The anesthetic
techniques consisted of a combination of local anesthesia
(1 % lidocaine), intravenous benzodiazepine (1.0–2.5 mg
of midazolam), and propofol (2–2.5 mg/kg). The dose of
anesthetic was adjusted according to the intraoperative
situation. Percutaneous ablation was performed accordingto our routine protocol. The parameters of ablation, in-
cluding ablation power, ablation time, and number of elec-
trodes, were adjusted according to the manufacturer’s
instructions, operator’s experience, and intraoperative CT
evaluation.
For tumors more than 5 cm in diameter, we usually
chose microwave ablation for HCC treatment; for tumors
less than or equal to 5 cm, we used RFA. Most patients
(78.9 %, 225 of 285) had cancerous lesions less than or
equal to 5 cm in diameter. Complete ablation was assessed
using intraoperative and postoperative contrast-enhanced
CT (Fig. 2), and additional ablation was added if necessary.
Five patients received palliative ablation in the combin-
ation group due to multiple lesions in the liver that were
detected via subsequent lipiodol CT.
Hepatic resection
Hepatic resection was carried out under general anesthesia,
and 4 experienced surgeons at Sun Yat-sen University
Cancer Center performed these procedures. Intraoperative
Table 1 Comparison of the clinical parameters between the
two groups of patients with hepatocellular carcinoma (HCC)





























≤3 cm 61 68
>3 cm and ≤5 cm 47 49
>5 cm and ≤7 cm 23 24
>7 cm and ≤10 cm 6 7
Alpha fetoproteina 0.292
≥400 ng/mL 34 45
<400 ng/mL 103 103






37.0 ± 17.5 38.9 ± 18.1
Albumin (g/L) 40.8 ± 4.3 41.6 ± 4.2 0.133
Prothrombin time (s) 12.6 ± 2.0 13.0 ± 2.1 0.075
Platelet count (×109/L) 128.2 ± 64.8 145.1 ± 60.0 0.022
Hemoglobin (g/L) 135.9 ± 16.2 138.7 ± 16.8 0.156
CA19-9 (U/mL) 140.4 ± 852.2 79.8 ± 531.0 0.469
aThe values are presented as number of patients. Tumor size, the largest lesion
in diameter.
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tumors, the remnant liver, and the possibility of a negative
resection margin; the surgeon then searched for new le-
sions. Various methods of hepatic resection were adopted
according to the scenario. After the operation, pathologic
examination was performed for all excised specimens to
confirm diagnosis and complete resection, which was con-
sidered the absence of microscopic tumor invasion and
negative resection margins. Three patients were found to
have incomplete resections due to new lesions detected
during hepatectomy.
The treatment principal after recurrence was similar
between the two groups. Hepatectomy, TACE, percutan-
eous thermal ablation, or conservative treatment was se-
lectively performed in cases of recurrence depending on
tumor location, tumor size, tumor number, liver func-
tion, and the general condition of the patient. For early
recurrent HCC, either hepatectomy or RFA was per-
formed according to the Barcelona Clinic Liver Cancer
staging classification [12]. For unresectable recurrent
HCC, palliative TACE, thermal ablation, or best support-
ive treatment was given. Recurrent patients who were
not treated according to the above treatment principals
were excluded from the surgery group.
Overall survival (OS) was measured from the date of
diagnosis of HCC to the date of death or last follow-up.
Recurrence-free survival (RFS) was defined as the interval
between the time of diagnosis of HCC to the last follow-
up or the time when a recurrent/residual tumor was diag-
nosed. Patients lost to follow-up were censored on the last
follow-up day. The last follow-up date was March 1, 2014.
Statistical analysis
The categorical characteristics were summarized and are
presented as proportion and frequencies. The continuous
variables are expressed as the mean values ± standard de-
viation, median values, or number of patients. Continuous
data were compared between the two groups by using the
independent t test, and categorical variables were com-
pared by using Pearson’s chi-square test or Yates’s correc-
tion for continuity. Survival was calculated by using the
Kaplan-Meier method and compared by using the log-
rank test. A two-tailed P value of <0.05 was considered
statistically significant. All statistical calculations were per-
formed with SPSS software version 18.0 (SPSS, Chicago,
IL, USA). The independent prognostic factors in predict-
ing survival were assessed by using a multivariate Cox
proportional hazards regression analysis.
Results
Survival analysis
The mean follow-up duration was 43.4 ± 25.9 (median,
39.1) months, and 13 patients were lost to follow-up.
The 1-, 3-, and 5-year OS rates were 95 %, 74 %, and 67 %
Fig. 2 Perioperative imaging of patients with HCC. a and b, viable lesions are not shown in different segments of the liver via preoperative CT.
c and d, it is very difficult to locate viable lesions in segments 6 and 7 of the liver via preoperative magnetic resonance imaging. e and f, two
additional tiny lesions with lipiodol depositions were detected in segments 6 and 7 of the liver (arrows) by using lipiodol CT after TACE. g and h,
two cancerous lesions were treated with radiofrequency ablation
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the surgery group, respectively (P = 0.004). The 1-, 3-, and
5-year RFS rates were 92 %, 69 %, and 61 % for the com-
bination group and 75 %, 58 %, and 44 % for the surgery
group, respectively (P = 0.001) (Fig. 3).In the multivariate analysis, treatment allocation
(hazard ratio [HR] = 1.810, 95 % confidence interval
[CI] = 1.215–2.697, P = 0.004), albumin level (HR = 1.819,
95 % CI = 1.233–2.685, P = 0.003), tumor size (HR = 1.732,
95 % CI = 1.160–2.587, P = 0.007), and tumor number
Fig. 3 Comparison of survival between the combination group and surgery group of HCC patients. a, the combination of TACE and
percutaneous thermal ablation improved the overall survival of patients with HCC compared with hepatectomy. b, the combination of TACE and
percutaneous thermal ablation improved the recurrence-free survival of patients with HCC compared with hepatectomy
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pendent prognostic factors for OS (Table 2). Treatment al-
location (HR = 1.999, 95 % CI = 1.341–2.980, P = 0.001),
albumin level (HR = 1.723, 95 % CI = 1.167–2.543, P =
0.006), tumor size (HR = 1.877, 95 % CI = 1.255–2.806,
P = 0.002), and tumor number (HR = 1.359, 95 % CI =
1.114–1.658, P = 0.002) were independent prognostic
factors for RFS (Table 2).Complications
Complications are shown in Table 3. More blood loss
and longer hospital stay were observed in the surgery
group than in the combination group. Major complica-
tions did not significantly differ between the two groups.Hemoglobin level decreased more significantly in the sur-
gery group than in the combination group (P < 0.001).
Additional tumors detected
Only 60 of the 137 patients in the combination group
had sufficient imaging data to confirm tiny HCC in
the liver. A total of 135 lesions with lipiodol depos-
ition were diagnosed as new HCC lesions in 22 of 60
patients via lipiodol CT after TACE, as confirmed by
radiologists in our team (Fig. 4). Twenty new lesions
were found in 11 of 148 patients in the surgery
group, as postoperatively confirmed via pathologic exam-
ination. Newly diagnosed tumors were ≤ 5 mm in diameter
in the combination group whereas ≤ 10 mm in diameter in
the surgery group.
Table 2 Univariate analysis of overall survival (OS) and recurrence-free survival (RFS) of the 285 HCC patients
Variable Number of patients OS (months) P RFS (months) P
Age 0.879 0.921
<65 years 238 79.4 ± 4.6 72.4 ± 4.6
≥65 years 47 77.9 ± 8.6 73.4 ± 9.4
Sex 0.163 0.141
Male 262 83.0 ± 4.3 76.4 ± 4.2
Female 23 54.0 ± 7.2 47.5 ± 8.1
Cirrhosis 0.911 0.806
Yes 250 80.4 ± 4.4 73.7 ± 4.3
No 35 67.6 ± 8.3 64.1 ± 8.8
Treatment allocation 0.012 0.004
Combinationa 137 91.2 ± 6.1 84.1 ± 6.0
Surgery 148 61.7 ± 3.8 57.1 ± 4.3
Tumor number <0.001 <0.001
1 128 80.4 ± 5.0 66.7 ± 3.9
2 93 73.3 ± 6.8 69.8 ± 7.2
3 49 82.2 ± 9.5 75.3 ± 8.6
4 15 31.8 ± 10.0 26.6 ± 7.7
CA19-9 0.088 0.093
Positive 113 71.0 ± 5.8 68.0 ± 6.1
Negative 172 84.1 ± 5.5 74.1 ± 4.9
Alpha fetoprotein 0.004 0.002
≥400 ng/mL 79 60.6 ± 6.7 56.6 ± 7.1
<400 ng/mL 206 87.2 ± 4.8 79.2 ± 4.5
Albumin 0.003 0.014
≥40 g/L 174 87.4 ± 5.4 76.8 ± 4.9
<40 g/L 111 65.3 ± 5.9 62.5 ± 6.2
Prothrombin time 0.018 0.011
≤13.5 s 217 85.0 ± 4.9 78.2 ± 4.8
>13.5 s 68 63.0 ± 6.8 58.2 ± 7.4
Platelet count 0.417 0.604
≥100 × 109/L 200 82.5 ± 4.9 74.0 ± 4.6
<100 × 109/L 85 72.1 ± 6.9 9.0 ± 7.5
Hemoglobin 0.456 0.239
≥120 × 1012/L 247 81.6 ± 4.4 75.5 ± 4.2
<120 × 1012/L 38 67.9 ± 9.3 51.6 ± 7.9
Maximal tumor size 0.009 0.004
≤3 cm 130 95.0 ± 5.4 88.2 ± 5.3
>3 cm 155 65.8 ± 4.8 56.1 ± 4.3
Hypersplenism 0.941 0.668
Yes 144 79.4 ± 6.2 73.6 ± 5.9
No 141 76.0 ± 5.0 71.8 ± 5.4
All values are presented as mean ± standard deviation. aCombination treatment includes ablation and hepatectomy.
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Major complications (cases [%]) 2 (1.5 %) 3 (2.0 %) 0.716
Bleeding volume (mL) 19.4 ± 42.0 327.0 ± 322.8 <0.001
Transfusion (mL) 5.1 ± 45.9 31.4 ± 114.8 0.013
HB decrease (mL) 8.9 ± 15.0 18.3 ± 15.6 <0.001
Hospital stay (days) 11.5 ± 6.9 18.7 ± 4.9 <0.001
The italic numbers reflected P value which was < 0.05
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Surgery for resectable HCC has been widely used for
many years. As new imaging techniques and technology
advances, imaging-guided minimally invasive therapies
for liver cancer have undergone rapid developments due
to their efficacy and minimal invasiveness [13].
Our present study indicated that the combination of
TACE and percutaneous thermal ablation improved the
survival of patients with HCC compared with hepatectomy.Fig. 4 Multiple tiny lesions detected by lipiodol CT. a, no cancerous
lesions were detected in contrast-enhanced CT prior to TACE. b,
multiple tiny lesions with lipiodol depositions (as shown in arrows)
were detected by using lipiodol CT after TACE in the same patientThe treatment modality was an independent prognostic
factor for survival. TACE plus RFA can be used to achieve
complete targeted HCC lesion necrosis; long-term survival
has also been reported [14, 15]. TACE alone was reported
to be comparable with RFA or hepatectomy for small single
HCC [16]. Thus, TACE combined with RFA was possibly
curative. Takuma et al. [9] found comparable OS rates be-
tween the two groups, and disease-free survival was super-
ior in the surgery group than in the combination group.
However, CT was performed 1 day after RFA, and there
was no lipiodol CT imaging. Thus, additional tiny HCCs
may not have been identified and treated in this study.
Tashiro et al. [14] reported similar survival rates between
the two therapies for patients with HCC ≤ 2 cm in diam-
eter. However, for patients with a single Child-Pugh class A
HCC larger than 2 cm in diameter, the disease-free survival
time was significantly longer in the subgroup of hepatec-
tomy than in the subgroup of RFA. Kim et al. [17] con-
cluded that for a single HCC (2 to 5 cm in diameter), RFA
combined with TACE resulted in a survival time similar to
that of patients undergoing hepatectomy. For patients with
early-stage HCC, Kagawa et al. [18] also stated that the OS
rates of patients treated with RFA combined with TACE
were similar to those of patients treated with hepatectomy.
We believe that combining TACE with percutaneous
thermal ablation is beneficial. First, it is difficult to diag-
nose all of the tiny HCCs with routine contrast-enhanced
CT or MRI. AFP level was significantly elevated in some
patients; however, cancerous lesions cannot always be de-
tected in imaging of these patients. We had to follow up
until these lesions became apparent. When these tiny le-
sions coexist with benign lesions, it is more difficult to de-
tect them using only AFP fluctuation. Second, during
hepatectomy, it is difficult for the surgeon to detect very
tiny lesions despite the routine use of intraoperative ultra-
sound. Some tiny HCCs were occasionally found in differ-
ent segments, and these lesions were also difficult to take
biopsy. Thus, they were less likely to be detected during
hepatectomy. We only found 20 additional HCCs in the
148 patients in the surgery group. Third, subsequent lipio-
dol CT can be used to detect additional tiny HCCs with
lipiodol deposition [6]. TACE combined with RFA was su-
perior to RFA alone in prolonging patient survival, and
the efficacy of TACE on HCC detection and treatment has
been demonstrated [8]. Microvascular invasion with satel-
lite lesions is an unfavorable prognostic factor for HCC
[19]; however, tiny HCC and satellite lesions can be de-
tected on lipiodol CT and then treated. TACE is useful for
treating multiple lesions within different lobes, usually
with incomplete necrosis. Complete necrosis can be
achieved after thermal ablation, especially for local tumors.
This explains why TACE combined with thermal ablation
prolongs survival compared with hepatectomy. Fourth,
HCC tends to relapse in a multi-centric manner. The vast
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virus infection and/or cirrhosis, which remain in the
remnant liver after treatment. These factors limited the
repeated use of hepatectomy for recurrent patients.
Percutaneous thermal ablation, which is highly repeat-
able and less invasive to the liver parenchyma [20],
more thoroughly preserves the liver parenchyma and is
suitable for recurrent patients with poor performance
status and cirrhosis.
New lesions were detected in only one-tenth of all pa-
tients and were found in 36.7 % of the 60 patients with
complete data in our study. Additional cancerous lesions
were not confirmed in the other 77 patients of the com-
bination group; however, those lesions were ablated or
closely followed up. Tiny lesions can be detected earlier
and effectively treated with TACE and lipiodol CT in the
combination group. Thus, this modality may provide a
survival benefit. The surgery group had complete patho-
logic data; however, additional cancerous lesions were
only identified in 11 of the 148 patients; any other non-
detected lesions would lead to disease progression in the
other 137 patients. Lipiodol CT was not performed in
these patients, and many tiny lesions may not be identi-
fied. This may influence the efficacy of surgery because
surgeons have difficulty in locating tiny HCCs in this cir-
cumstance. Thus, more tiny HCCs can be detected and
treated by combining TACE with thermal ablation. Prior
to resection or local ablation, neoadjuvant therapies are
not recommended for HCC by some European experts
[21]. According to our study, after TACE, lipiodol CT as-
sists in the detection of additional cancerous lesions that
were missed on routine contrast-enhanced CT or MRI
imaging.
Tumor number and size were important factors in
TNM staging and were independent prognostic factors
in our study as well as in other studies [22–24]. There
was no difference in preoperative maximal tumor size
between two groups. In the combination group, more le-
sions were detected after TACE, and the total tumor
number increased more substantially; thus, the mean
tumor size became smaller. In the combination group,
only 60 patients with sufficient imaging data were avail-
able for the discovery and confirmation of new lesions
with lipiodol deposition; new tiny lesions in the other 77
patients were not confirmed as malignancies. In the sur-
gery group, the pathologic data were complete and can-
cerous lesions were confirmed for all patients. However,
lipiodol CT was not performed for these patients prior
to surgery, thereby potentially leaving tiny HCCs un-
detected. Thus, the real mean size in the combination
group was not definitively smaller than that in the sur-
gery group.
Additionally, maximal tumor size affects TNM staging
After TACE, the maximal tumor size in the combinationgroup changed and the total tumor number increased.
However, the maximal tumor size in the hepatectomy
group was stable. Thus, we only provide a preoperative
maximal tumor size for the survival analysis. Moreover,
some cancerous lesions were undetected and uncon-
firmed in both groups. These lesions were later identi-
fied with differing methods, and only some additional
lesions were confirmed. The median size of all of the tu-
mors is thus not given.
After TACE, newly diagnosed lesions with lipiodol de-
position on CT imaging cannot be verified via pathologic
examination. However, these lesions may be cancerous
and would thus require additional treatment or follow-
up. Using MRI [25], contrast-enhanced CT, ultrasound,
AFP test, and biopsy, accurate differential diagnoses
were made for these additional lesions to exclude benign
disease. However, a small subset of tiny lesions may be
misdiagnosed as cancerous lesions and be over-treated.
With TACE and lipiodol CT, most malignant lesions can
be detected and treated. Cancerous lesions diagnosed
preoperatively in the same patient were confirmed and
effectively treated.
More precise techniques should be developed to further
differentiate tiny HCC with higher diagnostic confidence.
However, this is a retrospective study. A prospective multi-
center randomized study is needed.
In conclusion, we indicated that the combination of
TACE and percutaneous thermal ablation improved the
survival of patients with HCC compared with hepatec-
tomy. Lipiodol CT may assist in the detection of add-
itional cancerous lesions in the liver.
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